Home Cart Sign in  
Chemical Structure| 1382481-79-9 Chemical Structure| 1382481-79-9

Structure of ML289
CAS No.: 1382481-79-9

Chemical Structure| 1382481-79-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML 289 is a selective negative allosteric modulator at mGlu3 receptors with IC50 of 660 nM.

Synonyms: VU0463597

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML289

CAS No. :1382481-79-9
Formula : C22H23NO3
M.W : 349.42
SMILES Code : O=C(N1C[C@H](CO)CCC1)C2=CC=C(C#CC3=CC=C(OC)C=C3)C=C2
Synonyms :
VU0463597
MDL No. :MFCD25541754

Safety of ML289

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Related Pathways of ML289

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02212106 - Completed - -
NCT00947882 Lower Urinary Tract Symptoms (... More >>LUTS) Less << Phase 2 Completed - -
NCT00947882 - Completed - -
NCT02212106 Influenza, Human Phase 4 Completed - United States, California ... More >> Site 286 Los Angeles, California, United States, 90036 United States, Idaho Site 289 Boise, Idaho, United States, 83642 United States, Missouri Site 287 Saint Louis, Missouri, United States, 63141 United States, New York Site 285 Binghamton, New York, United States, 13901 United States, North Carolina Site 290 Durham, North Carolina, United States, 27704 Site 281 Raleigh, North Carolina, United States, 27609 Site 280 Winston-Salem, North Carolina, United States, 27103 United States, South Carolina Site 284 Charleston, South Carolina, United States, 29403 United States, Texas Site 283 Austin, Texas, United States, 78705 Site 282 Fort Worth, Texas, United States, 76135 Site 288 San Angelo, Texas, United States, 76904 Less <<
NCT01421511 Skin and Subcutaneous Tissue B... More >>acterial Infections Less << Phase 3 Completed - -
NCT00552344 Crohn Disease Phase 3 Completed - -
NCT02545543 Influenza, Human Phase 3 Completed - -
NCT01421511 - Completed - -
NCT02545543 - Completed - -
NCT00262522 Human Immunodeficiency Virus I... More >>nfections Less << Phase 3 Completed - -
NCT02214225 - Completed - -
NCT00552344 - Completed - -
NCT02154594 Gingivitis Phase 4 Completed - India ... More >> Tatyasaheb Kore Dental College and Research Centre Kolhapur, Maharashtra, India, 416 137 Less <<
NCT00262522 - Completed - -
NCT03697629 Multiple Myeloma in Relapse Phase 2 Not yet recruiting February 2020 -
NCT00024934 IgA Deficiency Phase 1 Completed - United States, Maryland ... More >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 Less <<
NCT01922856 Enteritis; Escherichia Coli, E... More >>nterotoxigenic Less << Phase 2 Completed - United States, Maryland ... More >> Johns Hopkins Center for Immunization Research Baltimore, Maryland, United States, 21205 Naval Medical Research Center Silver Spring, Maryland, United States, 20910 Less <<
NCT02897648 - Recruiting May 31, 2019 France ... More >> Groupe Hospitalier Paris Saint Joseph Recruiting Paris, Ile-de-France, France, 75014 Contact: BEAUSSIER Helene, PhD, PharmD    +33 1 44 12 70 38    hbeaussier@hpsj.fr    Contact: Mohamed CHERIFI, PharmD    +33 1 44 12 70 84    mcherifi@hpsj.fr Less <<
NCT02255812 Exploratory Behavior Not Applicable Completed - Switzerland ... More >> University Hospital Basel, Switzerland, CH-4031 Less <<
NCT02214225 Influenza, Human Phase 3 Completed - -
NCT02755532 Pharmacokinetics ... More >> Anesthetics, Local Less << Not Applicable Completed - -
NCT02121119 Hallux Valgus Phase 4 Completed - Chile ... More >> División de Anestesia - Facultad de Medicina Pontificia Universidad Católica Santiago, Región Metropolitana, Chile, 8330024 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.31mL

2.86mL

1.43mL

28.62mL

5.72mL

2.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories